1Chapelsky MC,Thompson K,Miller A.Effect of renal impairment on the pharmacokinetics of rosiglitazone[].Clinical Pharmacology and Therapeutics.1999
2Dicicco R,Allen A,Jorkasky D,et al.Lack of pharmacokinetic drug interaction between rosiglitazone(BRL 49653C)and metformin[].Clinical Pharmacology and Therapeutics.1998
3Shibuya A,Wantanabe M,Fujita Y,et al.An autopsy case of troglitazone-induced fulminant hepatitis[].Diabetes Care.1998
4Inglis AML,Miller AK,Thompson KA,et al.Coadiministration of rosigliatazone and acarbose(A): lack of a clinically relevant pharmacokinetic drug interaction[].Diabetes.
5Digby JE,Montague CT,Sewter CP,et al.Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes[].Diabetes.1998
6Digyb JE,Montague CT,Stewter CP,et al.Thiazolidinediones exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes[].Diabetes.1998
7De-Vos P,Lefebvre AM,Miller SG,et al.Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ[].The Journal of Clinical Investigation.1996
8Buckingham RE,Al-Barazanji KA,Toseland CDN,et al.Peroxisome proliferator-activated receptor agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats[].Diabetes.1998
9Schoonjans K,Martin G,Staels B,et al.Peroxisome proliferator-activated receptors , orphans with ligands and functions[].Current Opinion in Lipidology.1997
10Scheen AJ.Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s’achivements and future developments[].Drugs.1997
